I pay attention to what management communicates. They told us, "Accordingly, we cannot provide any assurance that we will effect the proposed business combination and related financing transactions. If we are unable to complete the proposed transactions or identify and complete another strategic or financing transaction in the first half of 2023, we may elect or be required to pursue a reorganization or seek other protection under the federal bankruptcy code."
I have said, many times, that I want to have a basis for my "dream theories." I can handle being wrong about something, as long as I have a justifiable reason for my conclusion.
I think that the supportive data that can be harvested from the ACTIV-5 final report, coupled with the CMML study findings, and including our possibly comparable results to Gohibic in treating stage 6 patients (ACTIV-5 treated stage 5 AND 6 patients), that the FDA may find enough safety and efficacy data to make a favorable decision on approving a resubmitted EUA application.
But that will trash Pfizer's tens of millions of annual revenue dollars, especially if lenz is used with traditional vaccines. That would destroy the case of the mRNA proponents, in addition to taking market share away from Pfizer and Moderna in the US.
So I can see a pathway to our success even without the business combination, but only if the FDA is fair in awarding us an EUA. And as far as financing, I haven't seen more than what I estimate about $1M raised.
But management has said we needed to complete the business combination, and raise enough money to fund the combined company until a revenue stream is started.
We haven't announced any news about progress on the regulatory front, either here or in Australia, and we haven't even resumed our Controlled Equity Offering, let alone added to it, or announced a Public Offering. Nor can we capitalize on a 5:1 forward stock split, without news to entice investor buying.
The company has also not acknowledged any Humanigen connection to the Black Horse entities' investment in Baudax Bio. Their recent acquisition and business combination with TeraImmune could represent exactly the opportunity to compliment our effort with SAHMRI in CMML and hematology oncology.
I think I'm at a point right now, in early Q3, where I don't have enough substantiation to support my conviction in this company's success.
At the same time, and especially after Black Horse's investment in Baudax Bio, I have never been more excited and confident in our immediate and spectacular turn-around, which I think will enable me to fill an open sell order at almost 100X my invested capital, if I were to sell out at that level, which I don't plan to do.
But again, I pay attention to what management communicates. I've been severely disappointed every week recently where news has not been announced. But I am hopeful that the Baudax investment will be announced as a Humanigen transaction designed to maximize the work we have been doing with SAHMRI in Australia. And I hope this news will enable us to execute a 5:1 forward stock split, forcing a short squeeze.
News 
Market Data 
Discover 
AI
